利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

158 条记录 (耗时 0.03 秒)

    Fibroblast growth factor-14
    21.
    发明申请
    Fibroblast growth factor-14 审中-公开
    成纤维细胞生长因子-14

    公开(公告)号：US20040043024A1

    公开(公告)日：2004-03-04

    申请号：US10662455

    申请日：2003-09-16

    申请人： Human Genome Sciences, Inc.

    发明人： Ralph Alderson ,  Robert Melder ,  D. Roxanne Duan ,  John M. Greene ,  Patrick J. Dillon

    IPC分类号： C07K014/50 ,  C07H021/04 ,  A61K039/395

    CPC分类号： C07K14/50 ,  A61K38/00 ,  A61K48/00 ,  C12N2799/026 ,  G01N2333/50

    摘要： The present invention relates to a novel human protein called Fibroblast Growth Factor 14, and isolated polynucleotides encoding this protein. Also provided are vectors, host cells, antibodies, and recombinant methods for producing this human protein. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to this novel human protein.

    摘要翻译： 本发明涉及称为成纤维细胞生长因子14的新型人类蛋白质和编码该蛋白质的分离的多核苷酸。 还提供了用于产生该人蛋白质的载体，宿主细胞，抗体和重组方法。 本发明还涉及用于诊断和治疗与该新型人蛋白相关的疾病的诊断和治疗方法。

    Receptors for fibroblast growth factors
    22.
    发明授权
    Receptors for fibroblast growth factors 失效
    成纤维细胞生长因子受体

    公开(公告)号：US06384191B1

    公开(公告)日：2002-05-07

    申请号：US07834311

    申请日：1992-02-13

    申请人： Lewis T. Williams ,  Daniel E. Johnson ,  Pauline E Lee

    发明人： Lewis T. Williams ,  Daniel E. Johnson ,  Pauline E Lee

    IPC分类号： C07K1471

    CPC分类号： C07K14/71 ,  A61K38/00 ,  G01N33/74 ,  G01N2333/50 ,  G01N2333/71 ,  G01N2500/00

    摘要： A fibroblast growth factor (FGF) receptor including a basic fibroblast growth factor receptor has been purified. Various forms have been identified including soluble forms lacking any transmembrane segment. DNA sequences encoding full-length fibroblast growth factor receptors and polypeptides comprising a portion of an FGF-R ligand-binding domain have been isolated and sequenced. These DNAs include DNAs encoding for a basic FGF-R and a human FGF-R and are operably linked to control sequences and expressed in a culture of a compatible host transformed, transfected or electroporated by a cloning vehicle containing the DNA sequence. The invention also comprises antibodies to the receptor, methods of synthesizing the growth factor receptor proteins, methods for providing analogs of the fibroblast growth factor receptors. Methods for evaluating compositions which promote or inhibit fibroblastic growth factors and compositions which are agonistic or antagonistic to fibroblast growth factor receptors are also provided. Diagnostic and therapeutic uses are described.

    摘要翻译： 已经纯化了包含碱性成纤维细胞生长因子受体的成纤维细胞生长因子（FGF）受体。 已经鉴定了各种形式，包括不含任何跨膜片段的可溶形式。 已经分离并测序了编码全长成纤维细胞生长因子受体的DNA序列和包含一部分FGF-R配体结合结构域的多肽。 这些DNA包括编码碱性FGF-R和人FGF-R的DNA，并且与对照序列可操作地连接，并在通过含有DNA序列的克隆载体转化，转染或电穿孔的相容宿主的培养物中表达。 本发明还包括对受体的抗体，合成生长因子受体蛋白质的方法，提供成纤维细胞生长因子受体类似物的方法。 还提供了评估促进或抑制成纤维细胞生长因子的组合物和对成纤维细胞生长因子受体具有激动作用或拮抗作用的组合物的方法。 描述诊断和治疗用途。

    Method for measuring fibroblast growth factor-23 and reagent therefor
    24.
    发明授权
    Method for measuring fibroblast growth factor-23 and reagent therefor 有权

    公开(公告)号：US12092637B2

    公开(公告)日：2024-09-17

    申请号：US16549387

    申请日：2019-08-23

    申请人： Hitachi Chemical Diagnostics Systems Co., Ltd.

    发明人： Koji Uzawa ,  Emiko Suzuki ,  Kazuyuki Ikeda ,  Kazuki Morita

    IPC分类号： G01N33/543 ,  G01N33/538 ,  G01N33/74

    CPC分类号： G01N33/54333 ,  G01N33/538 ,  G01N33/54326 ,  G01N33/74 ,  G01N2333/50

    摘要： A method for measuring fibroblast growth factor-23 (FGF-23) in a sample, which comprise the following steps:



    (1) reacting, in an aqueous medium, FGF-23 in a sample with magnetic particles, a first antibody or a fragment thereof which binds to FGF-23, and a second antibody or a fragment thereof which binds to FGF-23, to form on the magnetic particles an immunocomplex comprising the first antibody or a fragment thereof which binds to FGF-23. FGF-23, and the second antibody or a fragment thereof which binds to FGF-23;
    (2) collecting the magnetic particles in the reaction mixture after step (1) by magnetic force, and separating the magnetic particles collected by magnetic force from the other components; and
    (3) measuring the immunocomplex on the magnetic particles separated in step (2).




    The present invention provides a method for measuring FGF-23 in a sample, which have a high sensitivity and have a wide measurement range.

    NOVEL FGFR3 FUSION
    28.
    发明申请
    NOVEL FGFR3 FUSION 审中-公开
    新的FGFR3融合

    公开(公告)号：US20160375023A1

    公开(公告)日：2016-12-29

    申请号：US15264900

    申请日：2016-09-14

    申请人： Astellas Pharma Inc.

    发明人： Atsushi Suzuki ,  Makoto Asaumi ,  Kazuhisa Tsunoyama ,  Kouichi Nishimura ,  Akifumi Norinaka ,  Tomohiro Yamauchi ,  Masayasu Yoshino ,  Hiroaki Yoshizaki

    IPC分类号： A61K31/506 ,  C07K14/47 ,  G01N33/74 ,  A61K31/4439 ,  C12Q1/68 ,  C07K14/71 ,  A61K31/496

    CPC分类号： A61K31/506 ,  A61K31/4439 ,  A61K31/496 ,  C07K14/47 ,  C07K14/71 ,  C07K2319/00 ,  C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/57407 ,  G01N33/57423 ,  G01N33/74 ,  G01N2333/50

    摘要： The present invention aims to elucidate a polynucleotide as a novel responsible gene for cancer and aims to thus provide a method for detecting the polynucleotide and a polypeptide encoded by the polynucleotide and a detection kit, a probe set, and a primer set for the detection. The present invention also aims to provide a pharmaceutical composition for treating cancer. The method detects a fusion gene composed of a portion of an FGFR3 gene and a portion of a TACC3 gene or a fusion protein encoded by the fusion gene. The primer set, the probe set, or the detection kit comprises a sense primer and a probe set designed from the portion encoding FGFR3 and an antisense primer and a probe set designed from the portion encoding TACC3. Since an inhibitor of the polypeptide exhibits antitumor effect, a pharmaceutical composition for treating cancer which is positive for either the fusion gene or the polypeptide is provided.

    摘要翻译： 本发明旨在阐明多核苷酸作为癌症的新型负责基因，目的在于提供一种检测多核苷酸的方法和由多核苷酸编码的多肽以及用于检测的检测试剂盒，探针组和引物组。 本发明还旨在提供一种治疗癌症的药物组合物。 该方法检测由FGFR3基因的一部分和TACC3基因的一部分或融合基因编码的融合蛋白构成的融合基因。 引物组，探针组或检测试剂盒包括有义引物和由编码FGFR3的部分和反义引物设计的探针组，以及由编码TACC3的部分设计的探针组。 由于多肽的抑制剂表现出抗肿瘤效果，因此提供了用于治疗对融合基因或多肽呈阳性的癌症的药物组合物。